VYNE Therapeutics (VYNE) Earnings Date, Estimates & Call Transcripts → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free VYNE Stock Alerts $2.67 +0.02 (+0.75%) (As of 05/10/2024 ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Earnings SummaryUpcoming Earnings DateAug. 12EstimatedActual EPS (Feb. 29) -$0.20 Beat By $0.30 Consensus EPS (Feb. 29) -$0.50 Get VYNE Therapeutics Earnings AlertsEnter your email address below to receive the latest news and earnings results for VYNE and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueVYNE Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.VYNE Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… VYNE Therapeutics Analyst EPS EstimatesCurrent Year EPS Consensus Estimate:($1.00) EPSNext Year EPS Consensus Estimate: ($0.96) EPSVYNE Earnings Date and InformationVYNE Therapeutics last posted its quarterly earnings results on February 29th, 2024. The reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.50) by $0.30. The firm earned $0.08 million during the quarter, compared to analysts' expectations of $0.15 million. VYNE Therapeutics has generated ($5.45) earnings per share over the last year (($5.45) diluted earnings per share). Earnings for VYNE Therapeutics are expected to grow in the coming year, from ($1.00) to ($0.96) per share. VYNE Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 12th, 2024 based off prior year's report dates.Read More VYNE Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 8/12/2024Estimated)------- 2/29/2024Q4 2023($0.50)($0.20)+$0.30($0.20)$0.15 million$0.08 million11/13/2023Q3 2023($0.76)($1.85)($1.09)($1.69)$0.15 million$0.11 million8/14/2023Q2 2023($1.99)($3.08)($1.09)($3.07)$0.10 million$0.14 million5/11/2023Q1 2023($2.50)($1.74)+$0.76($1.74)-$0.10 million3/9/2023Q4 2022($3.24)($2.60)+$0.64($1.87)$0.12 million$0.01 million11/10/2022Q3 2022($2.88)($2.88)-($0.16)$0.10 million$0.17 million Get the Latest News and Ratings for VYNE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for VYNE Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/12/2022Q2 2022($3.24)($2.52)+$0.72($0.13)$0.30 million$0.13 million5/12/2022Q1 2022($2.88)($2.88)-($0.40)$0.55 million$0.18 million3/17/2022Q4 2021($3.96)($3.96)-($0.22)$4.09 million$2.29 million11/10/2021Q3 2021($5.94)($6.48)($0.54)($0.41)$4.67 million$4.09 million 8/12/2021Q2 2021($6.48)($6.30)+$0.18($0.39)$6.19 million$4.26 million VYNE Therapeutics Earnings - Frequently Asked Questions When is VYNE Therapeutics's earnings date? VYNE Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 12th, 2024 based off last year's report dates. Learn more on VYNE's earnings history. Did VYNE Therapeutics beat their earnings estimates last quarter? In the previous quarter, VYNE Therapeutics (NASDAQ:VYNE) reported ($0.20) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.50) by $0.30. Learn more on analysts' earnings estimate vs. VYNE's actual earnings. How much revenue does VYNE Therapeutics generate each year? VYNE Therapeutics (NASDAQ:VYNE) has a recorded annual revenue of $420,000.00. How much profit does VYNE Therapeutics generate each year? VYNE Therapeutics (NASDAQ:VYNE) has a recorded net income of -$28.45 million. VYNE has generated -$5.45 earnings per share over the last four quarters. What is VYNE Therapeutics's EPS forecast for next year? VYNE Therapeutics's earnings are expected to grow from ($1.00) per share to ($0.96) per share in the next year. More Earnings Resources from MarketBeat Related Companies: Bolt Biotherapeutics Earnings Eyenovia Earnings Cara Therapeutics Earnings Unicycive Therapeutics Earnings NextCure Earnings Lexaria Bioscience Earnings DURECT Earnings JanOne Earnings CASI Pharmaceuticals Earnings Sensei Biotherapeutics Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Traders Sell but Investors Still Win After Palantir's EarningsTech Earnings Insights: Where Opportunity Meets UncertaintyApple’s Earnings Show Investors Its Strength and Its WeaknessCarvana’s Q1 Earnings: A Profitability U-TurnPayPal’s Strong Earnings Growth and Strategic Evolution GE Aerospace is Ready for Liftoff After Strong EarningsTaiwan Semiconductor Earnings: AI Dominance and Future Outlook This page (NASDAQ:VYNE) was last updated on 5/12/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsGold Set to EXPLODE!Gold Safe ExchangeShocking: One AI startup's revenue could surge 4,735%Manward Press[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICThe 2024 Gold Rush: Unleashing Market PotentialPriority Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VYNE Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
